Imipramine – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Imipramine is historically the most important antidepressant ever made: Roland Kuhn at Geigy noticed in 1958 that this antihistamine candidate unexpectedly lifted depressed patients’ moods, which kicked off the entire monoamine theory of depression and the modern era of psychiatric pharmacology. Mechanically it blocks the serotonin and norepinephrine pumps in roughly balanced fashion, while also blocking acetylcholine, histamine, and alpha-1 adrenergic receptors as side activities. Today it sees mostly historical and academic use, plus a niche role in nocturnal enuresis (bedwetting) in children. The cardiac sodium channel block makes overdose lethal, which is one reason SSRIs displaced it once they became available. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

The 1958 prototype TCA, historically foundational but superseded by cleaner tools at every research axis

Look, imipramine is the Adam compound of synthetic antidepressant pharmacology. Roland Kuhn’s 1958 Geigy observation that the dibenzazepine scaffold relieved depressive symptoms launched the monoamine hypothesis and gave the field its first real conceptual framework. That history is genuinely significant. What the rubric asks is something different: how compelling is THIS compound as an active bench target right now, and the honest answer is, not very.

The mechanism is completely characterized and has been for decades. SERT inhibition at roughly 1 nM Ki, NET inhibition at ~21 nM, plus a well-mapped off-target profile covering muscarinic M1, H1, alpha-1 adrenergic, and voltage-gated sodium channels. The off-target hits that were once clinical liabilities remain liabilities now, not research opportunities. Nobody’s building a new program around imipramine’s anticholinergic activity when you can isolate those mechanisms cleanly elsewhere with better-characterized probes.

The differentiation problem is the sharpest drag here. Imipramine is superseded by its own active metabolite: desipramine is a cleaner, more NET-selective secondary amine that most investigators reach for when they want a TCA probe for norepinephrine transporter work specifically. For SERT-selective work, the entire SSRI class exists. For balanced dual inhibition, duloxetine and venlafaxine offer better tolerability and considerably cleaner pharmacology. Imipramine loses on almost every axis to something developed after it. Thats not a knock on historical significance, its just the reality of a 67-year-old compound in a mature drug class where every successive generation improved on the scaffold.

Where it retains real value is narrow: positive control in pharmacology assays requiring the canonical first-generation TCA, CYP2D6 and CYP2C19 probe substrate work, and research programs specifically examining the TCA class for historical comparison or mechanistic archaeology. The evidence base is genuinely solid, sixty-plus years of replicated clinical data, FDA approval across MDD, enuresis, and panic disorder, robust translational signal. But that signal describes clinical applications modern practice has largely moved past, and solid old evidence doesn’t make a compound interesting.

We think the honest landing for imipramine is important reference compound with narrow active bench utility. The evidence quality and translational signal keep the score from falling further, but the novelty floor and severely penalized differentiation pull it squarely into the same tier as piracetam: historically central to the field, currently deprioritized by most investigators chasing something with more headroom.

Novelty: 15
Mechanism promise: 22
In-category differentiation: 15
Evidence quality: 65
Translational signal: 65
Research bench value: 45

Rationale Imipramine scores hard at the bottom of novelty and differentiation because it’s a 1958 compound outcompeted by its own active metabolite (desipramine) and the entire SSRI/SNRI class; evidence quality and translational signal are genuinely solid but for indications modern practice has largely moved past, producing an overall that sits in the same tier as piracetam.

Tricyclic antidepressant (tertiary amine; first synthetic antidepressant)

The first synthetic antidepressant; the parent compound of the TCA class and the historical reference for monoamine theory of depression.

Abstract

Imipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 50-49-7; molecular formula C19H24N2; molecular weight 280.41) is a dibenzazepine tertiary amine TCA developed at Geigy by Roland Kuhn in 1958, the first synthetic compound demonstrated to relieve depressive symptoms in clinical trial. The historical observation underpinned the catecholamine hypothesis of depression and launched modern psychopharmacology. SERT and NET affinities are balanced (SERT Ki approximately 1 nM, NET Ki approximately 21 nM); the active metabolite desipramine is a NET-preferring secondary amine. Off-target activity parallels amitriptyline: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 11 to 25 hours; metabolism is via CYP2D6 and CYP2C19. Approved for major depressive disorder; clinical use today focuses on enuresis (bedwetting) in children (low-dose for anticholinergic and alpha-1 effects on bladder) and panic disorder. The TCA cardiotoxicity profile is the principal limitation. Used as the historical reference TCA and the prototype monoamine reuptake inhibitor in pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-218Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.